Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 January 2024 | Story Leonie Bolleurs | Photo Born2shoot
Dr Tommie van Zyl, Prof Philippe Burger and Prof Francis Petersen
At the launch of NovaLogix, a company co-owned by the UFS and ZZ2, were, from the left, Dr Tommie van Zyl, CEO of the ZZ2 Group, and Prof Philippe Burger, Dean of the Faculty of Economic and Management Sciences, and Prof Francis Petersen, Vice-Chancellor and Principal.

The University of the Free State (UFS) recently (17 January 2024) launched NovaLogix in collaboration with ZZ2, a well-known South African fresh produce company.

This new company, co-owned by the university and ZZ2, aims to develop and produce a probiotic used in the production of fresh produce to enhance plant health and growth. Projects include a focus on improved production techniques, product registration, commercialisation, and improved recipes.

Members of the university’s management structures were present at the formal launch of NovaLogix – which took place on the UFS Bloemfontein Campus – including the Vice-Chancellor and Principal, Prof Francis Petersen; the Deputy Vice-Chancellor: Research and Internationalisation, Prof Vasu Reddy; and the Senior Director of the Directorate Research Development, Dr Glen Taylor. The deans of the two faculties that will be mainly involved in this partnership were also present, namely Prof Paul Oberholster, the Dean of the Faculty of Natural and Agricultural Sciences, and Prof Philippe Burger, the Dean of the Faculty of Economic and Management Sciences.

Among the attendees representing ZZ2 were Dr Tommie van Zyl, the Chief Executive Officer of the ZZ2 Group, Piet Prinsloo, Executive Manager at ZZ2, as well as Wiam Haddad, the new CEO of NovaLogix.

Co-creation and more sustainable outcomes

In his welcoming remarks, Prof Petersen stated that this event marks the culmination of a five-year journey that began in 2019 when he, Prof Burger, and Prof Danie Vermeulen, former Dean of the Faculty of Natural and Agricultural Sciences, first visited ZZ2 to initiate closer collaboration and cooperation.

He is of the opinion that the relationship with ZZ2 is ideally suited to assist the university in realising the core values of Vision 130, the university’s strategic intent to reposition the institution as one of the leading universities in South Africa by 2034.

The knowledge, experience, and expertise that ZZ2 brings to the partnership, complement the exciting and impactful research done by the university’s academics across a range of disciplines. - Prof Francis Petersen

Prof Petersen said that the UFS values partnerships with the private sector, and he considers ZZ2 to be a knowledge partner with co-creation as a key component in this collaboration.

“Working together on a challenge makes the solution more sustainable. I believe that innovation and this co-creation approach will generate outcomes that transform the agricultural sector and impart knowledge to the next generation,” he stated.

“The knowledge, experience, and expertise that ZZ2 brings to the partnership complement the exciting and impactful research conducted by the university’s academics across a range of disciplines. I am looking forward to a partnership that will grow from strength to strength,” concluded Prof Petersen.

Breakthrough developments in the pipeline

According to Dr Van Zyl, ZZ2 would like to continue building a future with the university based on a symbiotic relationship. “We want to ensure that our strengths as an organisation are put to good use,” he said, expressing a strong conviction that there will be breakthrough developments with this initiative.

This work will align with ZZ2’s ‘Work with nature’ journey that began more than two decades ago, steering away from conventional, industrial agriculture towards a system that aims to farm in harmony with nature. “It is important that we nurture nature while using her resources,” he said.

He is excited to work with the university, exploring improved techniques and technologies to find more effective ways towards a sustainable future. “Knowledge partners are important in this journey,” he stated.

Building on existing collaborations

In September 2022, the university entered into a collaboration agreement with ZZ2. The partnership between the two entities included the establishment of FreeFarm Innovation, a company that in turn has a holding in NovaLogix and is designed to leverage the strengths, capabilities, skills, and resources of both parties. Part of the operations of FreeFarm Innovation included opportunities for research, commercialisation, and the enhancement of agricultural products. This has come into effect in projects on, for example, business operations, agricultural sustainability, and innovative approaches to growing fruit and vegetables, to name but a few.

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept